Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Self-citationThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Self-citationPancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“In addition, treatment with p38 MAPK inhibitor leads to an increase in insulin transcription in the presence of either GLP-1 or Ex-4 and this effect is mediated via the CRE site (Kemp and Habener, 2001).”
BackgroundInfluentialβ-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
“duced cytokine-induced apoptosis in purified islets -cells exposed to IL-1 , TNF , and interferon- (9).”
BackgroundResultInfluentialGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Self-citationRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Self-citationChang, A. M., & Halter, J. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2002 · Cited by 585
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citationNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Self-citationGrowth and Regeneration of Adult β Cells Does Not Involve Specialized Progenitors
Teta, M., Rankin, M. M., Long, S. Y., Stein, G. M., & Kushner, J. A. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.011 · Cited by 551
“Mice were injected with 24 nmoles per kg bodyweight daily in the subcutaneous space similar to established protocols (De Leon et al., 2003; Li et al., 2003).”
MethodBrubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
“Zucker diabetic fatty rats GLP-1 (34) Human islet cells GLP-1 (47) Rat islet cells (cytokines) Exendin-4 (44) RINm5F islet cells (palmitate) GLP-1/exendin-4 (46) Min6 islet cells (hydrogen peroxide) GLP-1 (41) INS-1 islet cells (staurosporine) Exendin-4 (42) FIG.”
BackgroundInfluentialSelf-citationInternational Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
“Activation of GLP-1 receptor signaling also promotes proliferative and anti-apoptotic actions in the endocrine pancreas, providing a potential opportunity for interventions directed at expanding -cell mass in subjects with diabetes (Li et al., 2003; Drucker, 2003).”
BackgroundSelf-citationGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
“Treatment of rat islets with the GLP-1 analog NN2211 reduced cytokine-induced apoptosis in vitro (76), and GLP-1 increased cell survival and reduced caspase activation in BHK fibroblasts expressing a transfected GLP-1R (77).”
BackgroundInfluentialSelf-citationNielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Self-citationMechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430
“One example might prove to be longacting analogues of GLP-1 (or inhibitors of the enzyme DPP IV that degrades GLP-1) that will be in clinical use to enhance insulin-secretion but could have additional beneficial effects on beta-cell mass by stimulating proliferation and inhibiting apoptosis [ 65 , 66].”
BackgroundSelf-citationDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
“Moreover, GLP-1R–deficient β cells exhibit enhanced sensitivity to apoptotic injury, whereas pharmacological activation of GLP-1R signaling attenuated β cell death in mice in vivo, as well as in cultures of purified rat β cells studied ex vivo (70).”
BackgroundSelf-citationRegulation of pancreatic beta-cell mass
Bouwens, L., & Rooman, I. (2005) · Physiological Reviews · doi:10.1152/physrev.00025.2004 · Cited by 411
In Vivo and In Vitro Characterization of Insulin-Producing Cells Obtained From Murine Bone Marrow
Tang, D.-Q., Cao, L.-Z., Burkhardt, B. R., Xia, C.-Q., Litherland, S. A., Atkinson, M. A., & Yang, L.-J. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1721 · Cited by 388
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Self-citationIslet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
“Finally, GLP-1 has recently been shown to delay beta cell apoptosis in Zucker diabetic rats, an animal model of diabetes [38], as well as in streptozotocin-treated mice and cytokinetreated rat islets in vitro [ 41 ].”
BackgroundBertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
“Previously published work has shown that exendin-4 can promote b-cell proliferation and islet neogenesis (Li et al., 2003; Gedulin et al., 2005).”
BackgroundTarbell, K. V., Petit, L., Zuo, X., Toy, P., Luo, X., Mqadmi, A., Yang, H., Suthanthiran, M., Mojsov, S., & Steinman, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061631 · Cited by 342
“Insulinotropic actions of glucagon-like peptide-I [7-37] administered to diabetic and non-diabetic human subjects.”
BackgroundAge-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Adaptive β-Cell Proliferation Is Severely Restricted With Advanced Age
Rankin, M. M., & Kushner, J. A. (2009) · Diabetes · doi:10.2337/db08-1198 · Cited by 327
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
“Previous studies have demonstrated that the stimulation of GLP-1R signaling can ameliorate hyperglycemia, improve insulin secretion, and reduce βcell apoptosis in db/db diabetic mice [55,18] as well as wt mice that were treated with multiple low doses of STZ [56], in a manner similar to the present study.”
Self-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
“GLP-1 reduces cell death in islets b-cells, fibroblasts and neurons (Farilla et al., 2002; Li et al., 2005; Li et al., 2003; Perry et al., 2002a; Perry et al., 2002b).”
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Self-citationBensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
“…al., 2004) and in animal models of T2D (Farilla et al., 2002) likely through the activation of PKB (Buteau et al., 2004) and/or an antioxidant effect (Li et al., 2003; Liu et al., 2012; Pospisilik et al., 2003) - Potential restoration of -cell function in the islets of T2D individuals in vitro…”
BackgroundTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Thomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F., & Mark, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135723 · Cited by 283
“It is possible therefore to postulate that increasing basal levels of GLP-1 may provide the conditions for -cell regeneration (Farilla et al., 2003; Li et al., 2003).”
BackgroundGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Drucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
“glycemia after exposure to streptozotocin (10).”
BackgroundSelf-citationUpregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
Hennige, A. M., Burks, D. J., Ozcan, U., Kulkarni, R. N., Ye, J., Park, S., Schubert, M., Fisher, T. L., Dow, M. A., Leshan, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18581 · Cited by 262
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
“Previous studies demonstrated that cAMP-mediated pathways are central to the antiapoptotic actions of GLP-1 in b-cells (Li et al. 2003, Perry & Greig 2003, Baggio & Drucker 2007), and the neuroprotective effects of cAMP-elevating agents are observed in many neuronal cells (D’Mello et al. 1993, Mena…”
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C., Burcelin, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420518 · Cited by 256
Self-citationLi, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247
Self-citationGlucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
“Conversely, GLP-1R activation reduces APOPTOSIS in isolated β cells in response to cytokines, and in experimental models of β-cell injury”
BackgroundSelf-citationCytokines and β-Cell Biology: from Concept to Clinical Translation
Donath, M. Y., Størling, J., Berchtold, L. A., Billestrup, N., & Mandrup-Poulsen, T. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0033 · Cited by 222
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Lipotoxicity disrupts incretin-regulated human β cell connectivity
Hodson, D. J., Mitchell, R. K., Bellomo, E. A., Sun, G., Vinet, L., Meda, P., Li, D., Li, W.-H., Bugliani, M., Marchetti, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68459 · Cited by 210
“University Hospitals (CER 05-028 [05-065]) (Geneva, Switzerland).”
Wang, Q., Li, L., Xu, E., Wong, V., Rhodes, C., & Brubaker, P. L. (2004) · Diabetologia · doi:10.1007/s00125-004-1327-5 · Cited by 206
“Although originally described as a potent stimulator of glucose-dependent insulin secretion, recent studies [1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13] have shown that the intestinal hormone GLP-1 also prevents the onset of diabetes and ameliorates existing diabetes through a mechanism that includes enhancement of beta-c…”
BackgroundResultExendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function
Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G., & White, M. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508307200 · Cited by 208
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Liu, W. J., Xie, S. H., Liu, Y. N., Kim, W., Jin, H. Y., Park, S. K., Shao, Y. M., & Park, T. S. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.186866 · Cited by 209
“An antiapoptotic effect mediated by GLP-1R in and neural cells after hyperglycemia or other insults has also been suggested (Li et al., 2003, 2009).”
BackgroundSturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 202
“…and neogenesis (Buteau et al., 1999; Edvell & Lindström, 1999; Xu et al., 1999; Perfetti et al., 2000; Moldrup et al., 2001; Farilla et al., 2002; Rolin et al., 2002), and some studies indicate that it also inhibits b-cell apoptosis (Bregenholt et al., 2001; Farilla et al., 2002; Li et al., 2003).”
BackgroundLi, L., El-Kholy, W., Rhodes, C. J., & Brubaker, P. L. (2005) · Diabetologia · doi:10.1007/s00125-005-1787-2 · Cited by 206
“Importantly, exendin-4 treatment also reduces cytokine-induced apoptosis in purified rat beta cells [17].”
BackgroundResultInfluentialVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Dexamethasone Induces Cell Death in Insulin-Secreting Cells, an Effect Reversed by Exendin-4
Ranta, F., Avram, D., Berchtold, S., Düfer, M., Drews, G., Lang, F., & Ullrich, S. (2006) · Diabetes · doi:10.2337/db05-1220 · Cited by 195
Deacon, C. F., Ahrén, B., & Holst, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1091 · Cited by 194
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 183
Self-citationIslet Transplantation for Brittle Type 1 Diabetes: The UIC Protocol
Gangemi, A., Salehi, P., Hatipoglu, B., Martellotto, J., Barbaro, B., Kuechle, J. B., Qi, M., Wang, Y., Pallan, P., Owens, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02234.x · Cited by 184
Suarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M., & Rabinovitch, A. (2008) · Diabetes · doi:10.2337/db08-0688 · Cited by 187
“GLP-1 was synthetic human GLP-1 [7-36] amide (Bachem, Torrance, CA).”
MethodInsulin Sensitizing and Insulinotropic Action of Berberine from Cortidis Rhizoma
Ko, B.-S., Choi, S. B., Park, S. K., Jang, J. S., Kim, Y. E., & Park, S. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1431 · Cited by 181
McLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1628 · Cited by 183
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178
Receptors and effects of gut hormones in three osteoblastic cell lines
Pacheco-Pantoja, E. L., Ranganath, L. R., Gallagher, J. A., Wilson, P. J., & Fraser, W. D. (2011) · BMC Physiology · doi:10.1186/1472-6793-11-12 · Cited by 171
“Among other actions, GLP-1 has an important role in apoptosis, differentiation and intracellular effects on calcium in human pancreatic islet cells [14,15].”
BackgroundChapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“In contrast, GLP1R activation inhibits apoptosis in other cell types including islet beta cells, cardiomyocytes and neurons [46–48].”
BackgroundSelf-citationGLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 158
Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 161
Expansion of adult β-cell mass in response to increased metabolic demand is dependent on HNF-4α
Gupta, R. K., Gao, N., Gorski, R. K., White, P., Hardy, O. T., Rafiq, K., Brestelli, J. E., Chen, G., Stoeckert, C. J., & Kaestner, K. H. (2007) · Genes & Development · doi:10.1101/gad.1535507 · Cited by 161
Dickson, L. M., & Rhodes, C. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00031.2004 · Cited by 159
β-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity
Mezza, T., Cinti, F., CEFALO, C. M. A., Pontecorvi, A., Kulkarni, R., & Giaccari, A. (2019) · Diabetes · doi:10.2337/db18-0856 · Cited by 178
Rosenberg, L. C., Lipsett, M. A., Yoon, J., Prentki, M., Wang, R., Jun, H., Pittenger, G. L., Taylor, D., & Vinik, A. I. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000143270.99191.10 · Cited by 173
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 157
Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 155
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 159
Ferdaoussi, M., Abdelli, S., Yang, J.-Y., Cornu, M., Niederhäuser, G., Favre, D., Widmann, C., Regazzi, R., Thorens, B., Waeber, G., et al. (2008) · Diabetes · doi:10.2337/db07-1214 · Cited by 167
Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 154
“…Ex-4 to the GLP-1R leads to its interaction with the guanine triphosphate (GTP)-binding protein Gs, resulting in the activation of adenylyl cyclase and increased production of intracellular cAMP in the pancreas (Li et al. 2003), which has likewise been confirmed in PC 12 cells (Perry et al. 2002b).”
BackgroundMethodSelf-citationTherapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 161
Self-citationRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
TCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142
Self-citationNutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Sanz, C., Vázquez, P., Blázquez, C. P., Barrio, P. A., Álvarez, M., & Blázquez, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2009 · Cited by 140
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Self-citationKaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 139
Holz, G. G., & Chepurny, O. G. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 144
Koehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 136
“In contrast to prosurvival effects of GLP-1R signaling in rat and human -cells and cell lines (25, 26), Ex-4 did not attenuate cytotoxicity induced by indomethacin (Fig.”
BackgroundResultSelf-citationBose, M., Oliván, B., Teixeira, J., Pi-Sunyer, X., & Laferrère, B. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9696-3 · Cited by 151
“GLP-1 receptors have been identified on β-cells of both rats and humans [34,35], and studies have demonstrated that disruption of the GLP-1 receptor results in enhanced apoptosis of β-cells [36].”
Background
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.